Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3512)
Drug Name
Mavacamten
Synonyms SAR-439152; SAR 439152; SAR439152; MYK-461; MYK 461; MYK461
Indication Hypertrophic cardiomyopathy [ICD11: BC43] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 273.33 Topological Polar Surface Area 61.4
Heavy Atom Count 20 Rotatable Bond Count 4
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
Cross-matching ID
PubChem CID
117761397
CAS Number
1642288-47-8
TTD Drug ID
D0D1ZF
Formula
C15H19N3O2
Canonical SMILES
C[C@@H](C1=CC=CC=C1)NC2=CC(=O)N(C(=O)N2)C(C)C
InChI
InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
InChIKey
RLCLASQCAPXVLM-NSHDSACASA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Mavacamten Metabolite M10 DM018233 N. A. Unclear - Unclear 1 [3]
Mavacamten Metabolite M11 DM018234 N. A. Unclear - Unclear 1 [3]
Mavacamten Metabolite M13 DM018235 N. A. Unclear - Unclear 1 [3]
MYK-1078 DM016509
117761559
Unclear - Unclear 1 [3]
MYK-2210 DM016510
117764188
Unclear - Unclear 1 [3]
MYK-2241 DM015999
21958743
Unclear - Unclear 1 [3]
Mavacamten Metabolite M4 DM018232 N. A. Unclear - Unclear 2 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR010176 Mavacamten MYK-2210 Unclear - Unclear CYP2C9 [3]
MR010178 Mavacamten MYK-2241 Unclear - Unclear CYP3A4 ... [3]
MR010179 Mavacamten Mavacamten Metabolite M10 Unclear - Unclear Unclear [3]
MR010180 Mavacamten Mavacamten Metabolite M11 Unclear - Unclear Unclear [3]
MR010181 Mavacamten Mavacamten Metabolite M13 Unclear - Unclear Unclear [3]
MR010182 Mavacamten MYK-1078 Unclear - Unclear CYP3A4 ... [3]
MR010177 MYK-2210 Mavacamten Metabolite M4 Unclear - Unclear Unclear [3]
⏷ Show the Full List of 7 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[2]
References
1 ClinicalTrials.gov (NCT03470545) Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM). U.S. National Institutes of Health.
2 DrugBank(Pharmacology-Metabolism):Mavacamten
3 In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.